Supplementary methods from Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer
Publication
, Other
Crosby, EJ; Acharya, CR; Haddad, A-F; Rabiola, CA; Lei, G; Wei, J-P; Yang, X-Y; Wang, T; Liu, C-X; Wagner, KU; Muller, WJ; Chodosh, LA; He, X ...
March 31, 2023
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Crosby, E. J., Acharya, C. R., Haddad, A.-F., Rabiola, C. A., Lei, G., Wei, J.-P., … Hartman, Z. C. (2023). Supplementary methods from Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. https://doi.org/10.1158/1078-0432.22477266
Crosby, Erika J., Chaitanya R. Acharya, Anthony-Fayez Haddad, Christopher A. Rabiola, Gangjun Lei, Jun-Ping Wei, Xiao-Yi Yang, et al. “Supplementary methods from Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer,” March 31, 2023. https://doi.org/10.1158/1078-0432.22477266.
Crosby EJ, Acharya CR, Haddad A-F, Rabiola CA, Lei G, Wei J-P, et al. Supplementary methods from Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. 2023.
Crosby, Erika J., et al. Supplementary methods from Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. 31 Mar. 2023. Crossref, doi:10.1158/1078-0432.22477266.
Crosby EJ, Acharya CR, Haddad A-F, Rabiola CA, Lei G, Wei J-P, Yang X-Y, Wang T, Liu C-X, Wagner KU, Muller WJ, Chodosh LA, Broadwater G, Hyslop T, Shepherd JH, Hollern DP, He X, Perou CM, Chai S, Ashby BK, Vincent BG, Snyder JC, Force J, Morse MA, Lyerly HK, Hartman ZC. Supplementary methods from Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. 2023.